A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
brief summary
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to control the disease.
detailed description
Primary Objectives
Cohort 1A To evaluate the safety of ropeginterferon monotherapy and to determine the recommended phase 2 dose (RP2D) of ropeginterferon in patients with R/R MDS/AML with ≥5% blasts
Cohort 1B To evaluate the safety and determine the RP2D of ropeginterferon in combination with AZA in patients with newly diagnosed MDS/AML with ≥10% blasts
Secondary Objectives
To observe and record anti-tumor activity. Although the clinical benefit of ropeginterferon has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability.
Key secondary objective:
To assess the efficacy through EFS with AZA+ ropeginterferon separately in the R/R (Cohort 1A) and newly diagnosed patients (Cohort1B)
Other secondary objectives (separately for Cohort1A and Cohort1B):
1. CR+CRi (CRc) rates achieved within 4 cycles of therapy 2. Overall response rate (ORR; CRc+ morphologic leukemia free state) 3. Rate of MRD negative CRc by multiparameter flow cytometry (MFC) at 10-4 4. To determine duration of response (CRc and OR) 5. To determine median duration of overall survival (OS) 6. To determine rates of HSCT after study therapy